摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-2-Ethoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid | 222554-55-4

中文名称
——
中文别名
——
英文名称
(+/-)-2-Ethoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid
英文别名
3-[4-[(6-chloro-4-oxo-2,3-dihydro-1H-quinazolin-2-yl)methoxy]phenyl]-2-ethoxypropanoic acid
(+/-)-2-Ethoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid化学式
CAS
222554-55-4
化学式
C20H21ClN2O5
mdl
——
分子量
404.85
InChiKey
BTHWFMHPXNDZTC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    28
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    96.9
  • 氢给体数:
    3
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    (+/-)-methyl 2-ethoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate 在 sodium carbonate 作用下, 以73%的产率得到(+/-)-2-Ethoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid
    参考文献:
    名称:
    Benzothiazin and benzoxazin derivatives; their preparation and uses
    摘要:
    本发明涉及新型抗肥胖和降胆固醇化合物,它们的衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。更具体地说,本发明涉及一般式(I)的新型β-芳基-α-氧基取代烷基羧酸,其衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。
    公开号:
    US06130214A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVELLES COMPOSITIONS HETEROCYCLIQUES ET LEUR UTILISATION EN MEDECINE; PROCEDES DE LEUR FABRICATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:DR. REDDY'S RESEARCH FOUNDATION
    公开号:WO1999016758A1
    公开(公告)日:1999-04-08
    (EN) The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.(FR) La présente invention concerne de nouveaux composés anti-obésité et hypocholestérolémiques, leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et des compositions pharmaceutiquement acceptables les contenant. Plus particulièrement, cette invention se rapporte à de nouveaux acides alkylcarboxyliques $g(b)-aryl-$g(a)-oxysubstitués qui correspondent à la formule générale (I), ainsi qu'à leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et à des compositions pharmaceutiquement acceptables les contenant.
    本发明涉及新型抗肥胖和降低胆固醇化合物,其衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。更具体地说,本发明涉及一般式(I)的新型$g(b)-芳基-$g(a)-氧基取代的烷基羧酸,其衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。
  • Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
    申请人:DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC.
    公开号:US20010027198A1
    公开(公告)日:2001-10-04
    The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (1), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 1 The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.
    本发明涉及新型抗肥胖和降胆固醇化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂及含有它们的药学上可接受的组合物。更具体地,本发明涉及一般式(1)的新型β-芳基-α-氧基取代烷基羧酸、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂及含有它们的药学上可接受的组合物。本发明还涉及制备上述新型化合物、类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂、新型中间体和含有它们的制药组合物的方法。
  • NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    申请人:DR. REDDY'S RESEARCH FOUNDATION
    公开号:EP1124807A1
    公开(公告)日:2001-08-22
  • US6130214A
    申请人:——
    公开号:US6130214A
    公开(公告)日:2000-10-10
  • US6331627B1
    申请人:——
    公开号:US6331627B1
    公开(公告)日:2001-12-18
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)